Dr. Scherle is Chief Scientific Officer at Prelude. Prior to joining Prelude, Dr. Scherle was Group Vice President, Discovery Biology and Preclinical Pharmacology at Incyte Corporation and oversaw the target validation and drug discovery efforts for both the small and large molecule programs. Along with Dr. Vaddi, Dr. Scherle was one of the original team of scientists that joined Incyte in 2002. During her time at Incyte, she held roles of increasing responsibility and was involved in the NDA filing and approval of the JAK inhibitor, Jakafi, for the treatment of myelofibrosis and polycythemia vera, the approval of the JAK inhibitor, Olumiant, for rheumatoid arthritis, and the advancement of multiple NCEs for both targeted therapies and immuno-oncology mechanisms into clinical trials. Dr. Scherle received her PhD in immunology from the University of Pennsylvania and completed her postdoctoral training at the NIH. Previously, Dr. Scherle held scientific research positions with DuPont Pharmaceuticals Company and Bristol-Myers Squibb.